Aryaman Sharma

Aryaman Sharma

Auto-generated profile, based on publicly available information

Aryaman Sharma

Department of Medicine, Queen’s University, Kingston, Ontario, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Acta Radiologica
Verified
Journal Article
Closed access
VGV. Gupta
V. Gupta
MGMaynk Goyal
Maynk Goyal
NMN. Mishra
N. Mishra
SGS. Gaikwad
S. Gaikwad
ASA. Sharma
A. Sharma

30 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAryaman Sharma
Aryaman Sharma
LELauren Ellis
Lauren Ellis
KAKaytlin Andrews
Kaytlin Andrews
ABAlexander Brown
Alexander Brown
MFMargaret T. Fuller
Margaret T. Fuller
JPJames Purzner
James Purzner
Medulloblastoma (MB), the most common malignant pediatric brain tumor, remains difficult to cure upon relapse, with only 12.4% of patients surviving five years post-recurrence. While specific quiescent tumor cell populations are known to contribute to treatment-resistance, the molecular mechanisms that maintain quiescence remain poorly defined. Here, we identify the cell cycle inhibitor p57 as a regulator of quiescence and chemotherapy resistance in Sonic Hedgehog (SHH) MB. Nuclear p57 was enriched in Sox2+ and Nestin+ stem-like MB cells compared to proliferative Atoh1+ cells. Inducing p57 expression in SHH MB cells led to a six-fold increase in G 0 -phase cells and conferred resistance to the frontline chemotherapeutic vincristine. Clinically, dexamethasone is a glucocorticoid given to nearly all MB patients to manage cerebral edema and is administered with wide variability in timing and dosing. We show that dexamethasone significantly increased nuclear p57 levels and expanded the G 0 population in both Ptch1 +/− and Ptch1 +/− ; Trp53 −/− SHH MB mouse models. Pre-treatment with dexamethasone reduced vincristine sensitivity in SHH MB cells. Together, our findings reveal a clinically relevant and previously unrecognized mechanism of treatment resistance, whereby dexamethasone, despite its benefits in managing edema, may inadvertently contribute to tumor persistence or recurrence by driving a quiescent, drug-resistant state. Addressing the lack of standardization in steroid use or targeting p57 may improve treatment response and reduce recurrence in patients diagnosed with SHH MB.

12 August 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
ASAryaman Sharma
Aryaman Sharma
KAKaytlin Andrews
Kaytlin Andrews
ECElizabeth Calvert
Elizabeth Calvert
JHJacob Howran
Jacob Howran
RSRon Shore
Ron Shore
TPTeresa Purzner
Teresa Purzner
Objectives: To explore stakeholder perspectives on care coordination barriers and facilitators in regionalised neuro-oncology delivery, using brain tumours as a model for examining complex care pathways serving mixed rural-urban populations. Design: Reflexive thematic analysis of semistructured interviews from stakeholders across the neuro-oncology care pathway was used to identify themes of care system strengths, barriers to effective service delivery and priorities for system improvement. Setting: Regionalised Canadian health system serving one of Ontario’s largest catchment areas, characterised by predominantly rural populations and substantial geographic distances to tertiary care. Participants: 36 stakeholders purposively sampled to represent diverse roles across the care pathway, including family caregivers (n=6), healthcare providers from multiple specialties and care settings (n=28) and Indigenous community advisors (n=2). Results: Thematic analysis identified seven themes organised within two broad domains: care system strengths and barriers to care continuity. Care system strengths included three themes: responsive palliative care integration, provider dedication and compassionate commitment, and intra-institutional coordination infrastructure. Barriers to care continuity included four themes: insufficient pathway standardisation across settings; inadequate educational infrastructure for patients, families and providers; absent cross-institutional coordination infrastructure and limited regional clinical trial access. Participants described relatively coordinated processes within the tertiary centre, while communication and follow-up were more fragmented at interfaces with referring hospitals and community services, with participants describing patients becoming ‘lost in transitions’. Conclusions: Findings reveal how regionalised cancer systems can achieve localised coordination while experiencing fragmentation at interfaces between organisations. Participants described relatively coordinated processes within the tertiary centre, alongside more fragmented communication and follow-up across interfaces with referring hospitals and community services. These stakeholder perspectives highlight potential directions for service redesign, including standardised pathways, shared information systems and clearer cross-site accountability structures, which warrant future evaluation alongside consideration of resource allocation and local feasibility. Brain tumours, requiring rapid multidisciplinary coordination, expose these interface failures with clarity, offering transferable insights for improving integrated cancer care in regionalised health systems serving geographically dispersed populations.

11 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ASAryaman Sharma
Aryaman Sharma
KAKaytlin Andrews
Kaytlin Andrews
ECElizabeth Calvert
Elizabeth Calvert
JHJacob Howran
Jacob Howran
RSRon Joseph Shore
Ron Joseph Shore
TPTeresa Purzner
Teresa Purzner
Objectives: To explore stakeholder perspectives on care coordination barriers and facilitators in regionalized neuro-oncology delivery, using brain tumors as a model for examining complex care pathways serving mixed rural-urban populations. Design: Reflexive thematic analysis of semi-structured interviews from stakeholders across the neuro-oncology care pathway was used to identify themes of care system strengths, systemic barriers to effective service delivery and priorities for system improvement. Setting: Regionalized Canadian health system serving one of Ontario’s largest catchment areas, characterized by predominantly rural populations and substantial geographic distances to tertiary care. Participants: Thirty-six stakeholders purposively sampled to represent diverse roles across the care pathway, including family caregivers (n=6), healthcare providers from multiple specialties and care settings (n=28) and Indigenous community advisors (n=2). Results: Two main themes with subthemes emerged revealing a tension between localized excellence and systemic fragmentation. Theme 1 (Care System Strengths) included three subthemes: responsive palliative care integration, exceptional provider commitment, and effective intra-institutional communication. Theme 2 (Systemic Barriers to Care Continuity) included four subthemes: absent cross-institutional coordination infrastructure, insufficient pathway standardization, inadequate educational infrastructure for patients and providers and limited regional clinical trial access. Coordination mechanisms functioning effectively within the tertiary center consistently failed at interfaces with referring hospitals and community services, with participants describing patients becoming "lost in transitions." Conclusions: Findings reveal how regionalized cancer systems can achieve localized coordination while failing at system integration. The contrast between internal institutional coherence and external fragmentation suggests that effective care delivery requires deliberately extending coordination mechanisms across organizational boundaries through standardized pathways, shared information systems and defined cross-site accountability structures. Brain tumors, requiring rapid multidisciplinary coordination, expose these interface failures with clarity, offering transferable insights for improving integrated cancer care in regionalized health systems serving geographically dispersed populations. ARTICLE SUMMARY: Strengths and limitations of this study: Purposive sampling captured diverse stakeholder perspectives across the entire care continuum, from tertiary providers to community services and family caregivers Reflexive thematic analysis with independent coding by three researchers enhanced interpretive rigor and depth Brain tumors function as a model condition for examining care coordination due to their rapid progression and sensitivity to variability in care Single health system design limits direct generalizability but enables in-depth examination of coordination mechanisms in a regionalized context Geographic and organizational characteristics common to Canadian regionalized systems support transferability of findings Indigenous patient perspectives were represented through community advisors; direct patient voices from Indigenous communities would strengthen future work

29 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JHJacob Howran
Jacob Howran
ASAryaman Sharma
Aryaman Sharma
KAKaytlin Andrews
Kaytlin Andrews
DMDana Pople McCord
Dana Pople McCord
SSSabra K Salim
Sabra K Salim
TPTeresa Purzner
Teresa Purzner
Objective: To evaluate whether entrepreneurial methodologies applied to system-wide healthcare redesign were associated with improved survival, care timeliness, and rural-urban equity among patients with glioblastoma. Design: Non-randomized pre-post cohort study Setting: Tertiary neuro-oncology centre in Ontario, Canada Participants: Adults aged >18 years with histologically confirmed glioblastoma who underwent surgical resection between January 1, 2018, and February 28, 2025 Interventions: Implementation of the Integrative Brain Tumor Program (IBTP), a system-wide care intervention grounded in user-defined priorities and developed using a design thinking approach (empathize, define, ideate, prototype, test) integrated with operational frameworks adapted from early-stage innovation. System change was treated as a deliberate, deployable intervention that could be designed, launched, iteratively refined, and evaluated. Coordinated changes were embedded across healthcare services within existing infrastructure and resource constraints through a single centralized nurse navigator who standardized referrals, patient education, and real-time care coordination. Main Outcomes and Measures: Primary outcomes were one-year overall survival and time to postoperative MRI completion and radiotherapy initiation. Secondary outcomes assessed rural-urban equity in these measures. Associations were evaluated using Cox proportional hazards and Fine-Gray competing-risk models adjusted for age, sex, rurality, MGMT promoter methylation status, and calendar time. Results: Among 297 patients (244 pre-implementation, 53 post-implementation), baseline demographic and tumor characteristics were similar across cohorts. One-year overall survival was higher in the post-implementation cohort (60.4% vs 42.2%), corresponding to an adjusted hazard ratio of 0.61 (95% CI, 0.38-0.99). Postoperative MRI completion within 48 hours increased from 45.9% to 66.0% (adjusted cause-specific hazard ratio, 1.50; 95% CI, 1.05-2.14) with similar improvements observed at 7 days. Time to radiotherapy initiation did not differ between cohorts. Survival and MRI timeliness did not differ by rural or urban residence in either period, though rural radiotherapy delays were attenuated postimplementation. Conclusions: Systematic application of entrepreneurial methods to health system redesign was associated with clinically meaningful improvements in glioblastoma survival and care timeliness using minimal resources (single nurse navigator). These findings suggest that treating system change as an intervention grounded in user-defined priorities and oriented toward integrated systems rather than sequential process optimization can support sustainable transformation of complex, coordination-dependent care pathways and warrants evaluation in other disease settings.